ADARx Pharmaceuticals (ADRX) will participate in a fireside chat at the UBS Global Biopharma Conference on November 16, 2026.
President and Chief Executive Officer Zhen Li will speak in London at 2:00 p.m. GMT. A live webcast will be available on the Events page of the company’s investor website, with a replay archived on its website for 90 days.
ADARx Pharmaceuticals (ADRX) closed the sale of 3,937,500 additional IPO shares after underwriters fully exercised their option to purchase them. The shares were sold at $17.00 each, bringing the initial public offering to 30,187,500 shares and approximately $513.2 million in gross proceeds.
AbbVie also purchased 5,255,542 shares at $17.00 each in a concurrent private placement. Combined gross proceeds from the IPO and private placement were approximately $602.5 million. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank served as lead book-running managers; LifeSci Capital served as a book-running manager.
ADARx Pharmaceuticals (ADRX) priced its upsized initial public offering at $17.00 per share on September 24, 2026. ADARx is offering 26,250,000 common shares and expects approximately $446.3 million in gross proceeds before expenses. The underwriters have a 30-day option to buy up to 3,937,500 additional shares. Trading on the Nasdaq Global Select Market is expected to begin September 25, with the offering expected to close September 28, subject to customary closing conditions.
AbbVie has agreed to buy shares at $17.00 each in a concurrent private placement, up to a $100.0 million purchase limit. The purchase would give AbbVie approximately 4.9% of ADARx's outstanding common shares after both transactions close. ADARx expects approximately $535.2 million in combined gross proceeds before expenses, excluding any exercise of the underwriters' option. The private placement depends on the IPO closing; the IPO does not depend on the private placement.